ArticleMikrochimica acta2026
Construction of a novel AIE NIR fluorescence probe for monitoring lipid droplet dynamics during drug intervention and identification of disease models.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Real-time monitoring of lipid droplets (LDs) dynamics is critical for elucidating lipid metabolic pathways enabling early diagnosis of related diseases. In this study, we developed three novel donor-acceptor (D-π-A) type aggregation-induced emission (AIE) near-infrared (NIR) fluorescent probes, namely TPA-T1, TPA-T2, and TPA-T3. Among them, TPA-T2 exhibited the most pronounced fluorescence enhancement and excellent lipophilicity, enabling real-time visualization of LDs fluctuations in living cells. Experimental results demonstrated that TPA-T2 not only effectively tracked LDs dynamics but also revealed the functional involvement of LDs in cell death pathways such as ferroptosis and cuproptosis. Furthermore, TPA-T2 displayed a high degree of sensitivity to drug-induced metabolic changes, effectively distinguish normal liver tissue from fatty liver tissue, offering a valuable tool for pharmacodynamic assessment and early diagnosis of lipid metabolism-related diseases. When applied to tumor models, TPA-T2 was able to selectively label LDs within tumor tissues, underscoring its potential for studying tumor metabolic phenotypes. Overall, this work provides a novel molecular imaging tool for elucidating the mechanisms of metabolic diseases and offers broad application prospects in lipid metabolism research, cancer biology, and disease diagnostics.
Indexed as
Identifiers
41547660What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.